GLAUKOS®

TRANSFORMING VISION

Investor Presentation

MAY 2022

Disclaimer

All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management's current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, uncertainties regarding the duration and severity of the COVID-19 pandemic and its impact on our business or the economy generally; the reduced physician fee and ASC facility fee reimbursement rate finalized by CMS for 2022 for procedures utilizing the Company's iStent family of products and its impact on our U.S. combo-cataract glaucoma revenue; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, pandemic or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by government or third-party payors for procedures using the *iStent*®, the *iStent inject*® *W*, *iAccess*, *iPRIME*, our corneal cross-linking products or other products in development; our ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of our products; our ability to compete effectively in the highly competitive and rapidly changing medical device industry and against current and future technologies (including MIGS technologies); our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness.

These and other known risks, uncertainties and factors are described in detail under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the SEC on May 5, 2022. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this presentation are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this presentation, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.



WE'LL GO FIRST

Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.

GLAUKOS®
TRANSFORMING VISION

Attractive Financial Profile Provides Solid Foundation

GLAUKOS
TRANSFORMING VISION

TOTAL NET SALES
(in millions)



SALES MIX





SCALE

MARGINS

DIVERSIFICATION

BALANCE SHEET

GROSS MARGIN[1]



CASH AND EQUIVALENTS[2]
(in millions)

1 FY2014 GAAP & non-GAAP gross margin (75%); 1Q 2022 GAAP gross margin of 75% was adjusted for certain Avedro merger-related accounting and other adjustments - see Appendix for details; 2 2015 as of 12/31; 2022 as of 3/31

2022: Entering the Next Phase of Our Pioneering Journey

GLAUKOS
TRANSFORMING VISION

Expanding Core Offering & Potential

- Combo-cataract evolution
- Standalone glaucoma entry
- International glaucoma, iLink market-building initiatives take hold

Multiple Pharma Programs Move to Clinic

- Phase 2 trials planned
  (dry eye, presbyopia, iLink third-gen)
- IND/IDE filings planned
  (glaucoma and other programs)



New Pharma Products on Deck

- iDose TR Phase 3 data release planned
- NDA submissions planned (iDose TR, Epioxa (Epi-on))

Preparing for Future Growth

- New HQ; expanded manufacturing
- Global talent and expertise

Our Strategy for Long-Term Growth & Value Creation



1. SIGNIFICANT CLINICAL NEEDS
2. BIG IDEAS
3. SELF-FUNDING R&D TO DATE

4. EFFICIENT COMMERCIAL CHANNEL
5. PROVEN MARKET CREATOR
6. OPERATIONAL EXCELLENCE

Big Ideas: Disrupting Legacy Topical Eye Drop Therapy

GLAUKOS
TRANSFORMING VISION

Topical eye drops are often ineffective due to significant patient non-adherence

- Complex dosing regimens that are difficult to follow
- Forgetfulness
- Instillation challenges
- Impositions to quality of life
- Ocular surface disease, toxicity and other side effects

Patients need a better approach!



We're working to change convention with innovative dropless therapies that improve patient outcomes

Our Novel Technology Platforms



- Pharmaceuticals
- Surgical Devices

5 technologically distinct platforms

Pharma innovations dominate

Advancing the standard of care across our 3 franchises



6+ programs with key regulatory milestones in 2022

DISCLOSED PIPELINE PROGRAMS

4 (2015) ▶ **16** (2022)

R&D INVESTMENT SINCE 2018

$300M+

Unique Features of Our Differentiated Platforms



All platforms disrupt traditional paradigms and are designed to **generate multiple innovations** that offer advantages over the current standards of care (not a single eye drop)

1. **Pioneering firsts:** Maximizing proven ability to build durable, innovation-driven markets
2. **High productivity:** Multiple products per platform reduce costs per product, enhance success probability
3. **Expansion potential:** Expertise and capacity to add additional disruptive platforms

Our Focus

Large and/or underserved patient populations

Game-changing innovations – device, pharma or hybrid – based on patient need

- Pharmaceuticals
- Surgical Devices

Designed to Generate Layers of Future Growth



US MARKET OPPORTUNITY[1]

2021 **$2B**

2030+ **$60B**

- Pharmaceuticals
- Surgical Devices

1 Company estimates



A decade-long cascade of new, market-expanding products

Complemented by additional new platforms and programs yet to be disclosed

Delivered Through Our Leverageable Commercial Platform



Efficient, scalable platform ready to provide a range of quality products and services across a growing global customer base

GLOBAL COMMERCIAL PERSONNEL

2015 — 65

2021 — 260+

US SALES EFFICIENCY (in millions)

2014 — <$1

2019 — ~$3

COUNTRIES WITH DIRECT SALES



NEAR-TERM PIPELINE PRODUCTS COMING INTO EXISTING SALES FORCE

iAccess Trabecular Trephine

iPRIME VISCODELIVERY SYSTEM

iStent infinite

iDose TR

iLink on2 CROSS-LINKING PROCEDURE

iStent Platform: MIGS Pioneer & Innovation Leader

GLAUKOS
TRANSFORMING VISION



Industry's **most comprehensive offering** of micro-surgical, tissue-sparing solutions, providing a full range of options **to fit each surgeon's individual glaucoma treatment algorithm**

COMMERCIAL PRODUCTS & DISCLOSED PIPELINE PROGRAMS

	PRODUCT/PROGRAM	PATIENT	STATUS	
Combo-Cataract	iStent / iStent inject / iStent inject W	Mild-to-Moderate Glaucoma with Cataract	Approved (2012 / 2018 / 2020)	
Standalone	iStent infinite	Refractory Glaucoma Standalone	FDA submission filed	
	iStent infinite	Glaucoma Standalone	IDE pending	
	PreserFlo	Advanced-Refractory Glaucoma Standalone	PMA non-approvable; review ongoing	

20+ Years of clinical experience

200+ Peer-reviewed publications on iStent technology

Nearly **1M** iStent devices implanted worldwide

iAccess™ Launched in Q1 2022

iAccess
Trabecular Trephine

Tissue-sparing, minimally-invasive approach

iAccess is designed to deliver multiple outflow channels through the trabecular meshwork into Schlemm's canal

When medically necessary, precision goniotomy with iAccess is designed to be unrestricted in its ability to create numerous ectomies across multiple clock hours, providing an extensive opening to Schlemm's canal, while preserving up to 95% more anatomy vs other tissue removal procedures

Commenced U.S. commercial launch activities in late Q1 2022

iPRIME™ Receives FDA Clearance

iPRIME VISCODELIVERY SYSTEM

A viscoelastic delivery system

iPRIME is a minimally invasive viscoelastic delivery system that further supports the needs of physicians and patients

This complementary technology further expands Glaukos' broad portfolio of innovative ophthalmic solutions

iStent infinite: Powerful Standalone MIGS Indication

GLAUKOS
TRANSFORMING VISION

iStent infinite™



CLINICAL TRIAL RESULTS[1]

76% *of subjects achieved **20% or greater reduction in mean diurnal IOP** from baseline on same or lower ocular hypotensive medication burden*

13% *mean reduction in medication burden from baseline*

≥50% *of subjects achieved **30% or greater reduction in mean diurnal IOP** from baseline*

Highly favorable safety profile
(no explants, infections or device-related interventions or hypotony)

Most difficult to treat glaucoma patients

Average of 3.1 IOP lowering medications at baseline

Already failed average of 2 prior glaucoma surgeries

Targeting FDA clearance in mid-2022

iStent infinite is not approved by the FDA

1 US IDE open-label, single-arm study in a standalone procedure; 72 subjects with OAG uncontrolled by prior surgery; enrollment completed Oct 2019

iDose Platform: The Next Stage in Glaucoma Therapy



Designed to address ubiquitous patient non-adherence to and chronic side effects associated with topical medications **by providing 24/7, long-duration, robust efficacy with minimal side effects**

DISCLOSED PIPELINE PROGRAMS

PROGRAM	PATIENT	STATUS	
iDose TR	OHT-Refractory Glaucoma	Phase 3; NDA filing targeted for 2022	
iDose TREX	OHT-Refractory Glaucoma	Pre-clinical	
iDose Rock	OHT-Refractory Glaucoma	Pre-clinical	

Studies[1] show that

10-25%

of newly prescribed patients don't refill their 2nd prescription and

~40-60%

of newly prescribed patients are no longer taking their meds at the end of Year 1

Elevated IOP due to non-adherence leads to glaucoma progression and vision loss[2]; nearly 50% of glaucoma patients are prescribed 2 or more topical meds[3]

1 Quigley HA Glaucoma: What Every Patient Should Know 2011; Friedman DS et al Invest Ophthalmol Vis Sci. 2007; Glaucoma Research Foundation; 2 Leske C et al Arch Ophthalmol. 2003; 3 Market Scope 2021

iDose TR: Phase 2b Data at 36 Months

~70% were responders ***well controlled on iDose*** with the same or fewer topical IOP-lowering meds at 36 months vs screening, including patients on ***2 and 3 meds at screening***

► **8.5 mmHg** average IOP reduction at 36 months for iDose responders (SE), ***providing sustained dropless therapy***

RESPONDER AVERAGE IOP REDUCTION FROM BASELINE



Overall, iDose TR performed similarly to timolol at 36 months in terms of mean IOP reductions with fewer topical medications vs timolol

iDose TR is not approved by the FDA

iDose TR: Phase 2b Data at 36 Months

Well-tolerated

- ***No ocular hyperemia*** *(30-50%+ for topical PGAs)*
- ***No periorbital fat atrophy*** *(up to 70% incidence for topical PGAs)*
- ***No clinically significant corneal endothelial cell loss***
- ***Only 1 instance of iris color change*** *(~20% incidence for topical PGAs)*

2,190 eye drops

Administered per eye per protocol in the control arm with twice-a-day timolol over 36 months vs one administration of iDose

- Patients are generally poorly compliant with IOP-lowering eye drops
- iDose design implies 100% compliance once administered
- Improved compliance with glaucoma medications has been associated with better outcomes in glaucoma disease

iDose TR is not approved by the FDA

iLink Platform: Bio-Activated Pharmaceuticals



Only therapy proven to slow or halt progression of keratoconus; without effective treatment, **1 in 5** progressive keratoconus patients **may require corneal transplant**[1,2]

COMMERCIAL PRODUCTS & DISCLOSED PIPELINE PROGRAMS

PRODUCT/ PROGRAM	PATIENT	STATUS
Photrexa (Epi-off)	Keratoconus	Approved (2016)
Epioxa (Epi-on)	Keratoconus	Phase 3; NDA filing targeted for 2022
iLink Third-Generation	Keratoconus	Phase 2; actively enrolling

Studies suggest that

72% & 98%

of corneal grafts fail within 20 years and at 30 years, respectively[1,2]

200+ peer-reviewed publications on iLink

1 Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113(9):1633-1638. 2. Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens. 2014;40(6):382-389

Epioxa (Epi-on): Phase 3 Trial Achieved Primary Efficacy Outcome

GLAUKOS
TRANSFORMING VISION

Designed to reduce treatment time and complexity, improving patient comfort and recovery time



Kmax is the point of highest corneal curvature, measured in Diopters (D)

Demonstrated Ability to Halt or Reduce Keratoconus Progression (n=279 eyes)

Achieved primary efficacy outcome *by demonstrating Kmax treatment effect of*

-1.0D

(p = 0.0004)

determined as prospectively defined least square mean Kmax change from baseline in treated arm vs. placebo arm at 6 months

In treatment arm, Kmax improved

0.2D

compared to ***worsening in Kmax by 0.8D in placebo arm*** *demonstrating ability of Epi-on to halt or reduce disease progression*

After initial 6-month follow-up,

98%

of placebo-randomized patients elected to cross-over to Epi-on treatment; for these patients, ***data showed Kmax improvement mean change of 0.3D at 6 months post-treatment***

Well-tolerated procedure

(majority of adverse events were mild and transient in nature; no change in corneal endothelial cell counts over course of trial)

Epi-on is not approved by the FDA

iLution Platform: Transdermal Dropless Therapy



Eyelid delivery offers **potential for easier administration, faster onset of action, fewer side effects and other benefits** vs prescription eye drops used to treat dry eye disease and other conditions, contributing to better compliance

DISCLOSED PIPELINE PROGRAMS

PROGRAM	PATIENT	STATUS
iLution Dry Eye	Dry Eye	Phase 2: actively enrolling
iLution Presbyopia	Presbyopia	Phase 2: actively enrolling
iLution Blepharitis	Demodex Blepharitis	Pre-clinical
Anterior Segment Candidates	Glaucoma	Pre-clinical

Potential target sites for iLution formulations



Lacrimal Function Unit: integrated system comprising the lacrimal glands, ocular surface (cornea, conjunctiva and meibomian glands) and lids, and the sensory and motor nerves that connect them.

Retina XR Platform: Addressing Conventional Therapy Drawbacks

GLAUKOS
TRANSFORMING VISION



Targeting **biodegradable, small-molecule implant with 6-12 months of efficacy**, designed to address shortcomings of conventional injections that impose tremendous treatment burdens on patients and contribute to lack of compliance

DISCLOSED PIPELINE PROGRAMS

PROGRAM	PATIENT	STATUS
IVT Multi-Kinase Inhibitor	AMD, DME	Pre-clinical
IVT Triamcinolone	DME	Pre-clinical

In the US, retinal disease affects approximately **28M people;** AMD and diabetic eye disease make up **89%** of this patient population[2]



Monthly or bi-monthly anti-VEGF injections are standard of care for AMD, DME and RVO but studies show that

39%

of patients are lost to follow-up within

2

years[1]

1 Long-term Experience With Intravitreal Anti-VDGF Treatment in Patients with AMD: Analysis of IRIS Registry Database (presented at 39th Annual Meeting of the American Society of Retina Specialists by Theodore Leng, MD); 2 Market Scope, 2019

Retina XR Candidate: Multi-Kinase Inhibitor

GLAUKOS
TRANSFORMING VISION

FA LEAKAGE CHANGE FROM BASELINE IN MULTI-KINASE INHIBITOR CANDIDATE AND PLACEBO-TREATED DL-AAA EYES

Leveraging 20+ years of injector system development expertise



10+ Months of Vascular Leakage Prevention In Rabbit Model of AMD

Commercial Execution in the Areas Most Visible to Investors…

GLAUKOS
TRANSFORMING VISION





30% 7-Year CAGR

…While Our Future is Just Beginning to Be Revealed

GLAUKOS
TRANSFORMING VISION



iStent
iStent inject
iStent inject W
Combo-Cataract

Photrexa (Epi-off)
iLink
CROSS-LINKING PROCEDURE



iLinkon2
CROSS-LINKING PROCEDURE
Epioxa (Epi-on)

iDose TR
OHT-Refractory

Standalone Therapies
iStent infinite
PRESERFLO MICROSHUNT
iAccess
Trabecular Trephine
iPRIME
VISCODELIVERY SYSTEM

Disruptive Programs For

Glaucoma
Dry Eye
Presbyopia
Keratoconus
Blepharitis
AMD, DME

iStent infinite, Epi-on, iDose TR and PreserFlo are not approved by the FDA

Summary: Glaukos is Different

Delivering **disruptive dropless therapies** designed to improve patient outcomes

Five distinct technology platforms, **dominated by pharmaceuticals** and designed to generate **waves of new market-expanding products**

Pursuing **game-changing therapies for large and underserved patient populations,** with R&D investments that have been self-funding

Commercialize with **best-in-class productivity and efficiency**, with a platform that is scaled and ready for more growth



GLAUKOS®

TRANSFORMING VISION

Appendix

GAAP to Non-GAAP Reconciliation - 1Q 2022				
	1Q 2022 GAAP Gross Margin	Amort. of Dev Tech Intangibles	Stock-based Comp Exp on Replacement Awards	1Q 2022 Non-GAAP Gross Margin
Net Sales	$ 67,681			$ 67,681
COGS	$ 17,063	$ (5,523)	$ (28)	$ 11,512
Gross Profit	$ 50,618	$ 5,523	$ 28	$ 56,169
Gross Margin	**75%**			**83%**

